Company profile: Enanta Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small-molecule anti-infective drug R&D, discovering and developing therapies including MAVYRET (glecaprevir/pibrentasvir), a hepatitis C virus protease inhibitor regimen requiring only eight weeks of treatment; EDP-514, a novel hepatitis B core inhibitor; zelicapavir (EDP-938), an RSV N-protein inhibitor in Phase 2 for pediatric and adult patients; EDP-323, an RSV L-protein inhibitor; and EDP-235, a 3CL protease inhibitor for COVID-19.
Products and services
- MAVYRET (glecaprevir/pibrentasvir): A two-drug, protease inhibitor regimen for hepatitis C virus requiring only eight weeks of treatment, delivering a compact, short-duration therapeutic course
- Zelicapavir (EDP-938): A Phase 2 N-protein inhibitor targeting respiratory syncytial virus, suitable for both pediatric and adult patients in ongoing studies evaluating RSV N-protein inhibition
- EDP-235: A variant-spanning 3CL protease inhibitor for COVID-19, demonstrating potent antiviral activity against various SARS-CoV-2 variants as a targeted small-molecule antiviral
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enanta Pharmaceuticals
Evaxion Biotech
HQ: Denmark
Website
- Description: Provider of AI-immunology™ platform-driven immunotherapies for cancer and infectious diseases, including EVX-01, a Phase 2 personalized cancer vaccine targeting patient-specific tumor antigens, and EVX-B1, a vaccine antigen against Staphylococcus Aureus, plus models PIONEER™, ObsERV™, and AI-DEEP™ for vaccine design and CPI response prediction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evaxion Biotech company profile →
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
Symbiomix
HQ: United States
Website
- Description: Provider of an anti-infective drug, a single-dose treatment, and innovative medicines for serious women's health infections that have long been neglected; a late-stage, privately held biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symbiomix company profile →
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
Nuclein
HQ: United States
Website
- Description: Provider of polymerase chain reaction test devices for infectious diseases, offering the DASH Rapid PCR System, a point-of-care platform that performs sample-to-answer PCR tests in 15 minutes for use in CLIA-waived environments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuclein company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enanta Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enanta Pharmaceuticals
2.2 - Growth funds investing in similar companies to Enanta Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enanta Pharmaceuticals
4.2 - Public trading comparable groups for Enanta Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →